Skye Share Price
NASDAQ: SKYE | Micro Cap | HealthcareSkye Stock Performance
Skye Share Price Chart
Skye Quarterly Profit & Loss
All figures in USD
Skye Annual Profit & Loss
All figures in USD
Skye Balance Sheet
All figures in USD Million
Skye Cash Flow
All figures in USD Million
Corporate Actions
About Skye
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Skye Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Nov 2026 | $1.33 | $1.01 | -23.48% |
Oct 2026 | $1.56 | $1.32 | -19.51% |
Sep 2026 | $1.78 | $1.64 | -18.37% |
Aug 2026 | $0.57 | $2.01 | +242.25% |
Jul 2026 | $0.68 | $0.59 | -12.52% |
Jun 2026 | $0.79 | $0.67 | -13.42% |
May 2026 | $0.79 | $0.78 | -12.82% |
Apr 2026 | $0.68 | $0.89 | +47.92% |
Mar 2026 | $0.77 | $0.60 | -19.11% |
Feb 2026 | $0.92 | $0.74 | -26.44% |
Jan 2026 | $0.74 | $1.01 | +35.75% |
Dec 2025 | $1.25 | $0.74 | -43.85% |